Champions Oncology reported record annual revenue of $59.4 million and full-year adjusted EBITDA of $1.6 million for fiscal 2026, with CEO Robert Brainin stating the company’s Corellia initiative is fully funded for fiscal 2027. Fourth-quarter revenue was $13.8 million, and adjusted EBITDA was $158,000, marking the fourth consecutive quarter of positive adjusted EBITDA. Services revenue reached a record $58.7 million, while data license revenue fell to approximately $800,000 from $4.7 million in fiscal 2025, which included a large one-time transaction. Gross margin improved to 51% in the fourth quarter from 41% a year earlier, helped by reduced outsourced radiopharmaceutical costs. The company ended the year with $4.9 million in cash and no debt, and management expects services growth to moderate while data revenue remains volatile, with some expected fourth-quarter recognition shifting into the first quarter of fiscal 2027.
Champions Oncology IncRecord revenue, positive adjusted EBITDA, improved gross margin, and fully funded Corellia initiative indicate strong financial performance and outlook.